Description: Lumos Diagnostics Holdings Limited operates as an integrated developer and manufacturer of point-of-care (POC) diagnostic tests. The company develops and manufactures proprietary and in-licensed POC diagnostic tests. Its products include FebriDx, a test that differentiates between bacterial and viral respiratory infections; and CoviDx, an antigen test for COVID-19. The company also develops and manufactures POC diagnostic tests on commercial contract basis, which include POC diagnostic tests, digital reader formats, and digital applications. It offers its products through distributors primarily in the North American and European markets. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Home Page: lumosdiagnostics.com
LDX Technical Analysis
Level 4
Melbourne,
VIC
3205
Australia
Phone:
61 3 9087 1598
Officers
| Name | Title |
|---|---|
| Mr. Samuel Lanyon | Exec. Chairman |
| Mr. Douglas Ward | Chief Exec. Officer |
| Mr. Barrie Lambert | Chief Financial Officer |
| Dr. Sacha Dopheide Ph.D. | Chief Technology Officer |
| Ms. Jennifer Christiansen | VP of Corp. Marketing & Communications |
| Ms. Sarah Glubka | Sr. Director of HR |
| Ms. Annie Bell | Sr. Director of Medical Affairs |
| Ms. Sue Hibbeln | Sr. Director of Regulatory Affairs |
| Mr. Paul Kase | Sr. VP of Commercial Operations |
| Ms. Melanie Jaye Leydin B.Bus, C.A., CA | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3947 |
| Price-to-Sales TTM: | 0.8849 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |